HER2-PET as a Precision Imaging Tool for Treatment With HER2-ADC in HER2-expressing mBC

The target population of the trial consists of female patients with mBC with known non-HER2-positive tumours or with unknown HER2-status. Patients can be included in the trial at the time of disease progression after at least one line of chemotherapy in the palliative setting, or within six months after completion of adjuvant therapy for primary breast cancer. Patients will be recruited at the Breast Clinics of the Karolinska Comprehensive Cancer Center in Stockholm, the Uppsala Academic Hospital in Uppsala, and Skåne University hospital in Sweden. Additional study sites may be added during the conduct of the trial and after approval of the regulatory agencies. Patients can be referred for study-related investigations from other sites, but all study-related investigations will be performed at one of the three above-mentioned clinics. Participants are eligible to participate in the study if they meet all the inclusion and none of the exclusion criteria listed below. Subject eligibility (that participants fulfil all inclusion criteria and do not meet any exclusion criteria) is established by the principal investigator or co- investigator that is involved in clinical care for the patient. When an eligible patient decides to participate in the study, all screening- and treatment related procedures will be initiated no earlier than after the informed consent form is signed. All patients will undergo a baseline study-specific HER2-PET and a tumour biopsy, the latter guided by the results from the HER2-PET. Lesions with sonographically feasible access and preferably with ABY-025 tracer uptake SUVmax ≥ 6 will be eligible for biopsy. In case no ABY-025 lesions are present or accessible for biopsy, a non-avid metastatic lesion is recommended for biopsy. For practical reasons, biopsies taken prior to the HER2-PET (no more than three months old and without exposition to systemic anti-cancer therapy or local radiotherapy to the specific lesion) can be used for study purpose. Patients with HER2-expressing fresh or archived tumour biopsy will be treated with T-DXd. A second HER2-PET will be done in all patients treated with T-DXd at the moment of treatment response evaluation after 9-12 weeks of treatment with T-DXd. An optional third HER2-PET and tumor biopsy will be done at the moment of disease progression on T-DXd.